Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome

The Randomized TOPIC Study : Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02099422

Acronym

TOPIC

Enrollment

500

Registered

2014-03-28

Start date

2013-01-31

Completion date

2016-01-31

Last updated

2014-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Antiplatelet Therapy, Coronary Stenting

Brief summary

Comparison of two antiplatelet strategies between months 1 and 12 after coronary stenting for ACS. Efficiency and tolerance évaluation

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Inclusion criteria

* ACS and coronary stenting one month ago

Exclusion criteria

* age under 18 and pregnancy

Design outcomes

Primary

Measure	Time frame
combined ischemic and hemorragic endpoint	12 months

Countries

France

Contacts

Primary Contactthomas cuisset, MD-PHD

thomas.cuisset@ap-hm.fr33(0) 491385981

Outcome results